Drug regimen enough to control immune disease after some bone marrow transplants

October 8, 2014

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response. Patients receive cyclophosphamide for two days after their bone marrow transplant, in addition to two other chemotherapy drugs given before the transplant.

Johns Hopkins Kimmel Cancer Center scientists first used to prevent severe graft-versus-host disease (GVHD) after bone marrow transplant involving haploidentical or "half-matched" transplants, a treatment first used in 2000 at the Cancer Center to treat leukemias and other blood cancers. The scientists began to use post-transplant cyclophosphamide in clinical trials of fully matched bone marrow transplants in 2004.

Now, the new multi-center study confirms that the post-transplant cyclophosphamide is safe and effective for people who have received fully-matched .

The shortened regimen, described online Sept. 29 in the Journal of Clinical Oncology, begins with intravenous busulfan and fludarabine, two chemotherapeutic drugs that wipe out a patient's immune system and prepare his or her body to receive donated marrow. After the transplant, patients receive two days of cyclophosphamide to prevent GVHD and rejection of the new bone marrow. Conventionally, most transplant patients get six months of immunosuppressive treatment for that purpose.

The bookended pre- and post-transplant treatments, which have been tested separately in other studies, already had promising track records in controlling cancer and preventing severe GVHD. Those successes led researchers from three hospitals, including Johns Hopkins, to combine the two therapies, says Leo Luznik, M.D., an associate professor of oncology at the Johns Hopkins University School of Medicine and leader of the study.

The new study enrolled 92 patients with high-risk blood cancers. Forty-five of the 92 patients received matched transplants from relatives, while 47 received matched transplants from unrelated donors.

After their transplants, 51 percent of the patients experienced grades II to IV acute GVHD, the milder form, and 15 percent of the patients experienced the severe forms of acute GVHD (grades III to IV). Only 14 percent of the patients developed chronic GVHD. A leading cause of post- transplant deaths, chronic GVHD affects approximately one-half of patients who receive conventional treatments.

Two years after their transplants, 67 percent of patients were living, and 62 percent of all patients were cancer-free.

Luznik says he was encouraged by the low rate of chronic GVHD seen with the regimen, noting that the percentages of acute GVHD cases are similar to those seen with the standard six-month regimen of immunosuppressive drugs. Reducing the post-transplantation treatment to two days with cyclophosphamide, he explains, "also allows for the earlier integration of other treatments."

For example, immunotherapies used to eradicate any remaining cancer could be started much sooner under this regimen, says Christopher Kanakry, M.D, a Kimmel Cancer Center researcher and co-first author of the study. "If you give patients immune cells to eradicate any remaining cancer cells that might be present," he says, "those immune cells would not be prevented from doing their job by ongoing immune suppression drugs that are being used in patients treated with conventional transplant approaches."

Luznik says that the researchers' next step will be to test the short course therapy in a phase III randomized clinical trial that would directly compare results in who receive the cyclophosphamide treatment with those who receive either a separate, experimental approach to prevent GVHD or the more traditional six-month immunosuppressive therapy.

Explore further: Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants

More information: Read the study in the Journal of Clinical Oncology. jco.ascopubs.org/content/early … 4.0625.full.pdf+html

Listen to a podcast discussing the study, produced by the Journal of Clinical Oncology. jco.ascopubs.org/content/early … 13.54.0625/suppl/DC2

Related Stories

Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants

November 13, 2013
Results of a Johns Hopkins study may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system ...

Half-matched transplants widen pool of donors for leukemia and lymphoma

July 7, 2011
Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical ...

No survival advantage with peripheral blood stem cells versus bone marrow

October 19, 2012
(Medical Xpress)—Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted ...

Novel drug regimen can improve stem cell transplantation outcomes

December 8, 2013
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to ...

B and T cell-targeting drug ameliorates chronic graft-versus-host disease in mice

October 1, 2014
Hematopoietic stem cells (HSCs) can differentiate into all types of blood cells, including red blood cells and immune cells. While HSC transplantation can be life saving for patients with aggressive forms of blood cancer ...

Immune cells found to prevent bone marrow transplant rejection

June 27, 2014
(Medical Xpress)—Cornell researchers have identified a type of immune system cell that prevents a patient's body from attacking donor cells after a bone marrow transplant, a condition called graft-versus-host disease (GVHD).

Recommended for you

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.